Is TRVI or TXMD more undervalued in 2026?

CirclFi compares Trevi Therapeutics, Inc. (TRVI) and TherapeuticsMD, Inc. (TXMD) using 13 institutional-grade valuation models. TRVI has a Quality of Company score of 4.2/10 while TXMD scores 6.5/10.

Which is a better buy — TRVI or TXMD?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TRVI and TXMD valuations compare?

TRVI at $14.14 and TXMD at $2.14 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TRVI vs TXMD Valuation Comparison 2026 — Intrinsic Value Analysis

TRVI

Pharmaceutical Preparations

Trevi Therapeutics, Inc.

Quality

4.2

out of 10

Value Trap

LOW

Price

$14.14

Last close

Models

7/13

Active

TXMD

Pharmaceutical Preparations

TherapeuticsMD, Inc.

Quality

6.5

out of 10

Value Trap

LOW

Price

$2.14

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	TRVI Fair Value	TRVI Upside	TXMD Fair Value	TXMD Upside
Bayesian DCF	Intrinsic	$3.83	-72.9%	$4.61	+115.3%
Earnings Power Value	Intrinsic	—	—	$0.75	-63.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.36	-97.4%	$1.98	-6.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TRVI vs TXMD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TRVI vs TXMD — Which Stock Is More Undervalued?

TXMD scores higher with a 6.5/10 quality rating vs TRVI's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Trevi Therapeutics, Inc. (TRVI) and TherapeuticsMD, Inc. (TXMD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TRVI currently trades at $14.14 with a QOC of 4.2/10, while TXMD trades at $2.14 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).